MarketPulse

metabolic health

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma A/S

Zealand Pharma Surges on Obesity Drug Breakthroughs and $700M Revenue Milestone

Zealand Pharma reports strong Q1 2026 results with obesity treatment advances, $700M collaboration revenue, and $200M share buyback program.
RHHBYZLDPYPhase 3 trialsclinical trial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Boehringer Ingelheim's Dual-Action Obesity Drug Survodutide Shows 16.6% Weight Loss

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.
ZLDPYclinical trial resultsweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Boehringer's Obesity Drug Survodutide Posts Strong Phase 3 Results, Boosting Zealand Pharma

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.
ZLDPYPhase 3 trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma A/S

Zealand Pharma Insiders Conduct Share Transactions; Regulatory Filing Signals Executive Confidence

Zealand Pharma discloses insider share transactions by executives and board members, providing investors transparency into management's confidence in the company's prospects.
ZLDPYbiotechnologyregulatory disclosure
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma Plants U.S. Flag in Cambridge with $M Research Hub by 2026

Zealand Pharma opens Cambridge research hub in September 2026 to expand AI-driven drug discovery and develop next-generation hybrid molecule therapeutics.
ZLDPYDOCpeptide therapeuticsobesity